If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Types == Fetuin-A was the first hepatokine to be described and correlated with increased inflammation and insulin resistance. Fetuin-B significantly increases hepatic steatosis and mediates impaired insulin action and glucose intolerance. ANGPTL8/betatrophin, initially proposed for its action on beta cell proliferation, although this effect has recently been brought into question. FGF-21 an insulin-sensitising hormone that is an appealing drug target because of its beneficial metabolic actions. Adropin is linked to macronutrient intake and estrogen. ANGPTL4 can inhibit lipoprotein lipase and activate cAMP-stimulated lipolysis in adipocytes.
Amid decolonisation and the Wind of Change, the Federation failed to become a Commonwealth realm and collapsed in 1963. Two years later, following prolonged dispute with Britain over the terms for full sovereignty, the mostly white government in Southern Rhodesia (or Rhodesia, following Northern Rhodesia's independence as Zambia) issued a Unilateral Declaration of Independence (UDI). The Rhodesian government, which had in it World War II veterans including the Prime Minister Ian Smith, attempted to emphasise Rhodesians' prior war record on Britain's behalf by declaring independence on Armistice Day, 11 November, at 11:00 local time. As part of its subsequent isolation of Rhodesia, the UK government banned the post-UDI authorities from taking part in the annual Armistice Day service at the Cenotaph in London. Smith's government organised its own Rhodesian wreath-laying ceremony there. Veterans of World War II and Malaya held many key positions in the Rhodesian Security Forces during the Bush War of the 1970s. After the country's reconstitution and recognised independence as Zimbabwe in 1980, Robert Mugabe's administration pulled down many monuments and plaques making reference to the dead of the First and Second World Wars, perceiving them as reminders of white minority rule and colonialism that went against what the modern state stood for. This view was partly rooted in the association of these memorials with those commemorating the British South Africa Company's dead of the Matabele Wars, as well as those memorialising Rhodesian servicemen killed during the Bush War.
== External links == Histology image: 08201loa – Histology Learning System at Boston University – "Connective Tissue: unilocular (white) adipocytes " Histology image: 04901lob – Histology Learning System at Boston University – "Connective Tissue: multilocular (brown) adipocytes"
Countercurrent exchange is a mechanism between two flowing bodies flowing in opposite directions to each other, in which there is a transfer of some property, usually heat or some chemical. The flowing bodies can be liquids, gases, or even solid powders, or any combination of those. For example, in a distillation column, the vapors bubble up through the downward flowing liquid while exchanging both heat and mass. It occurs in nature and is mimicked in industry and engineering. It is a kind of exchange using counter flow arrangement. The maximum amount of heat or mass transfer that can be obtained is higher with countercurrent than co-current (parallel) exchange because countercurrent maintains a slowly declining difference or gradient (usually temperature or concentration difference). In cocurrent exchange the initial gradient is higher but falls off quickly, leading to wasted potential. For example, in the adjacent diagram, the fluid being heated (exiting top) has a higher exiting temperature than the cooled fluid (exiting bottom) that was used for heating. With cocurrent or parallel exchange the heated and cooled fluids can only approach one another. The result is that countercurrent exchange can achieve a greater amount of heat or mass transfer than parallel under otherwise similar conditions. Countercurrent exchange when set up in a circuit or loop can be used for building up concentrations, heat, or other properties of flowing liquids.
Sources: en.wikipedia.org
. In practice, an inviscid flow is an idealization, one that facilitates mathematical treatment. In fact, purely inviscid flows are only known to be realized in the case of superfluidity. Otherwise, fluids are generally viscous, a property that is often most important within a boundary layer near a solid surface, where the flow must match onto the no-slip condition at the solid. In some cases, the mathematics of a fluid mechanical system can be treated by assuming that the fluid outside of boundary layers is inviscid, and then matching its solution onto that for a thin laminar boundary layer. For fluid flow over a porous boundary, the fluid velocity can be discontinuous between the free fluid and the fluid in the porous media (this is related to the Beavers and Joseph condition). Further, it is useful at low subsonic speeds to assume that gas is incompressible—that is, the density of the gas does not change even though the speed and static pressure change.
=== Distribution === These proteins, which typically contain 2-4 repeats of the β-thymosin sequence, are found in all phyla of the animal kingdom, with the probable exception of sponges The sole mammalian example, a dimer in mice, is synthesised by transcriptional read-through between two copies of the mouse β15 gene, each of which is also transcribed separately. A uniquely multiple example is the protein thypedin of Hydra which has 27 repeats of a β-thymosin sequence.
==== Fibers ==== The tubers of the mashua are a good source of dietary fiber. Mashua tubers contain approximately 5 to 7 g of fiber per 100 g of dry matter, depending on factors like growing conditions and the variety of mashua species. Dietary fiber content is supposed to have beneficial health effects and help relieve functional constipation, a common gastrointestinal problem in children.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.